

AUG-17-2005 13:47

P.14

Rec'd  
3/14/02

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE

SHEET 1 OF 2  
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets If Necessary)

DOCKET NO.: 1225/1D414US2  
APPLICANT: DAVID BERDSERIAL NO: 10/025,195  
FILING DATE: December 19, 2001**U.S. PATENT DOCUMENTS**

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
3f ↓	* 1. 5,484,596	01/16/96	Hanna, Jr., et al.	424	277.1	11/01/93
	* 2. 5,290,551	03/01/94	Berd	424	88	12/4/92
	* 3. 5,637,483	6/10/97	Dranoff et al.	424	93.21	6/23/94

**FOREIGN PATENT DOCUMENTS**

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
SU	* 4. WO 96/40173	19/12/96				

**OTHER REFERENCES****(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**\*EXAMINER  
INITIALSSU  
↓

- \*5. Marx, Jean L., Cancer Vaccines Show Promise at Last, Science, 245:813-816, 1989
- \*6. Hellström and Hellström, Tumor Immunology: An Overview, ANAYS, 690:24-33, 1993
- \*7. Dillman et al., "Irradiated, Cultured, Autologous Tumor Cells for Active Specific Immunotherapy", Proceedings of ASCO 14:546 (#1810), 1995
- \*8. Advani, S. et al., Oncology, 42:275-281, 1985
- \*9. Berd, D. et al., Proc. Am. Assoc. Cancer Res., 36:677-678, 1995
- \*10. Berd et al., Proc. Am. Soc. Clin. Oncol. 2:56, Abstract C-217
- \*11. Dunton, C.J., et al. Gynecologic Oncology, 68:111, 1998
- \*12. Fuglwara, H. et al., J. Immunol., 132:1571-1577, 1984

SHEET 1 OF

Re'd 8/3/03

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2003. OMB 0861-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/025,195
				Filing Date	December 19, 2001
				First Named Inventor	David Berd
				Art Unit	1842
				Examiner Name	Susan Nmn Ungar
Sheet	1	of	1	Attorney Docket Number	1225/1D414US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
su	CA	D. Berd et al., "Induction of Delayed-Type Hypersensitivity (DTH) to Ovarian Cancer Cells After Treatment With An Autologous (AUT), Hapten-Modified Vaccine," <i>Proceedings of the American Association for Cancer Research Annual</i> , vol. 39, March 1998, page 356.		
↓	CB	G. Garcia Manero et al., "Immunotherapy With an Autologous Cell Vaccine In Patients With Acute Myelogenous Leukemia (AML) in Second Remission," <i>Blood</i> , vol. 98, no. 11, November 2001, page 212b.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

*Susan for 9/18/05*

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE

SHEET 2 OF 2  
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 1225/1D414US2  
APPLICANT: DAVID BERDSERIAL NO: 10/025,195  
FILING DATE: December 19, 2001

- su*
- \*13. Mastrangelo, M. J. et al., Melanoma Research, 5:443, 1995
  - \*14. Nahas, F. et. al., Cell. Immunol., 54:241-247, 1980
  - \*15. Sato, T., Cancer Immunol. Immunother., 43:174-179, 1996
  - \*16. Benjamin et al., Recent Results in Cancer Research 47:408-414, 1974
  - \*17. Wiseman et al., Western J. Med. 151:283-288, 1989
  - \*18. MacLean et al., J. Immunotherapy 11:292-305, 1992
  - \*19. Longnecker, B.M., Soc. Biol. Therapy Annual Meeting, p. 31, 1992
  - \*20. Levin et al., (In Human Tumours In Short Term Culture: Techniques and Clinical Applications, P.P., Dendy, ed., Academic Press, London, pp. 277-280), 1976
  - \*21. Gillette et al. J. Reticulo Soc., 30:331-339, 1981
  - \*22. Sherman et al. J. Immunol., 123:501-502, 1979
  - \*23. Bystryn, Cancer Metastasis Rev., 9:81-90, 1990
  - \*24. Robins, Pathologic Basis of Disease, Fifth Edition, 1994, p. 1065
  - \*25. PR Newswire (May 22, 2000) 1023, AVAX Technologies' O-Vac(TM) cancer Vaccine Induces Positive Immunological and Clinical Outcomes in Patients with Advanced Ovarian Cancer

EXAMINER: *A. L. Jones*DATE CONSIDERED: *9/17/05***\*EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Filed in U.S. Serial No. 08/899,905; filed 07/24/97 and U.S. Serial No. 09/134,465; filed 8/14/98, or listed in Notice of References Cited.

M12251D414US23G144B.PRM